ALArne G. Lindgren

Arne G. Lindgren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arne G. Lindgren has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis

    by Mukul Sharma, Lizhen Xu, John W. Eikelboom, Alexander T. Cohen, Andrew M. Demchuk, Anna Członkowska, Arne G. Lindgren, Carlos A. Molina, Daniel Bereczki, Danilo Toni, et al.

    BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0–12.0) and 14.0 days (interquartile range, 10.0–20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33–5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33–4.48]), female sex (HR, 1.78 [95% CI, 1.00–3.16]), and age (HR per year, 1.04 [95% CI, 1.00–1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64–4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76–3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20–3.01]), and age (HR per year, 1.06 [95% CI, 1.03–1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02329327.

  • Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial

    by John W. Eikelboom, Lizhen Xu, Ashkan Shoamanesh, Qiang Dong, Teruyuki Hirano, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, et al.

    BACKGROUND: OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. METHODS: In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. RESULTS: Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85–1.44]; P =0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96–1.30]; P =0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93–1.13]; P =0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03–1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27–2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. CONCLUSIONS: Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05686070.

  • Incorporating Imaging Markers of Brain Health in Modeling of Functional Outcome After Acute Ischemic Stroke

    by Erik Lindgren, Luca Angeleri, Martin Bretzner, Anna K. Bonkhoff, Christina Jern, Arne G. Lindgren, Jane Maguire, Robert W. Regenhardt, Natalia S. Rost, Markus D. Schirmer

  • Molecular biomarkers in stroke recovery: Consensus-based core recommendations from the fourth Stroke Recovery and Rehabilitation Roundtable

    by Matthew A Edwardson, Robynne G Braun, Chad M Aldridge, Rufus Akinyemi, Stefan T Engelter, Israel Fernández-Cadenas, Cristina Gallego-Fabrega, Quentin Le Grand, Jane Maguire, Alexander H Nave, et al.

    Rationale: The 2017 Stroke Recovery and Rehabilitation Roundtable (SRRR) consensus statement on biomarkers identified genetic and blood biomarkers as a developmental priority for stroke recovery and rehabilitation. While progress has been made, this nascent field still lags behind other medical disciplines. Further development is critical because molecular biomarkers hold great promise to provide key insights into the neurobiological mechanisms of both spontaneous and treatment-induced stroke recovery. Such insights could lead to effective recovery biotherapeutics and help optimize the timing and delivery of therapies. Methods: A multidisciplinary taskforce of international experts with expertise in omics and stroke recovery identified and prioritized key focus areas. Consensus opinion was developed across 15 virtual meetings, 2 rounds of anonymous polling and a 2-day in-person meeting. Key recommendations were iteratively refined until full consensus was achieved by all taskforce members. Results: Our main recommendation is that there is a critical need for large-scale, multi-center, discovery-based omics studies to identify molecular targets in stroke recovery. To help achieve this goal we suggest ways to harmonize future studies including timepoints for data collection, outcome measures, and biospecimen selection. In addition, we address the limitations of current candidate biomarkers, translational challenges, emerging technologies, biomarker response to interventions, multi-site collaboration, and ethical concerns. Conclusions: There is a great need for collaborative efforts by the international neurorehabilitation community to collect and harmonize molecular biomarker data. The resulting discoveries will be foundational to precision neurorehabilitation and the development of recovery biotherapeutics to enhance recovery for stroke survivors.

  • Open Access

    Family history of stroke and cardiovascular diseases in early-onset cryptogenic ischaemic stroke

    by Maximilian C Sihvo, Pauli Ylikotila, Marialuisa Zedde, Rosario Pascarella, Tomi Sarkanen, Dalius Jatužis, Kristina Ryliškienė, Bettina von Sarnowski, Radim Licenik, Phillip Ferdinand, et al.

    Familial aggregation of stroke is well-documented, yet few studies have examined associations between stroke subtypes—particularly early-onset cryptogenic ischaemic stroke (eCIS)—and broader family history (FH) of cardiovascular disease. Such associations may provide insights into underlying etiologic mechanisms. In this multicentre case–control study, we included eCIS patients aged 18–49 years and matched stroke-free controls. We analysed the association between FH of stroke, venous thromboembolism (VTE), coronary artery disease (CAD), aneurysms and eCIS using multivariable logistic regression, with a subgroup analysis stratifying patients by high-risk patent foramen ovale (HR-PFO). We enrolled 508 eCIS patients (182 [36%] with HR-PFO) and 520 controls. Compared with controls, patients more frequently reported FH of stroke among first-degree relatives (FDR) (20% vs. 14%, P = .01) and grandparents (47% vs. 39%, P = .01), FH of early-onset stroke among FDR (5% vs. 2%, P = .01) and FH of early-onset VTE among FDR (5% vs. 2%, P = .003). In adjusted analyses, eCIS was associated with FH of stroke among FDR (OR 1.50; 95% CI, 1.04–2.16) and grandparents (1.50; 1.12–1.99), with FH of early-onset stroke among FDR (2.36; 1.11–5.04); and with FH of early-onset VTE among FDR (3.45; 1.47–8.13). eCIS was also associated with FH of VTE among FDR (1.80, 1.09–2.98) in the presence of HR-PFO. FH of CAD or aneurysms was not associated with eCIS. FH of stroke and VTE, particularly early-onset events and in the presence of HR-PFO, are associated with eCIS. These findings support familial predisposition and highlight prothrombotic mechanisms in eCIS. www.clinicaltrials.gov/study/NCT01934725

  • Open Access

    Basal Ganglia Calcifications in Stroke Patients and Control Subjects and Their Association With Small Vessel Disease

    by Maha Yektay Farahmand, Johan Wasselius, Arne G. Lindgren, Andreea Ilinca

    Background: The clinical relevance of basal ganglia calcifications (BGCs) in stroke is unclear, despite reported links to white matter changes (WMCs) and cerebral small vessel disease (SVD). We assessed BGC prevalence in stroke patients and control subjects and their association with WMC and stroke caused by small artery occlusion (SAO). Methods: We included 1430 patients with ischemic stroke (IS) or hemorrhagic stroke (HS) from the Lund Stroke Register. Stroke etiology was classified using the Trial of ORG 10172 in Acute Stroke Treatment criteria for IS and medical record review for HS. BGC and WMC were identified and graded on computed tomography (CT). We also reviewed CT scans from 1238 control subjects without known clinical or radiological evidence of IS or HS regarding BGC. Associations between BGC and WMC and SAO were analyzed using age‐ and sex‐adjusted logistic regression. Results: BGCs were identified in 10.1% of stroke patients and 11.9% of control subjects ( p = 0.13). BGCs were not associated with SAO (OR 1.13, 95% CI 0.65–1.96) and were more frequently observed in patients with subarachnoid hemorrhage (adjusted OR 3.12, p = 0.011). WMCs were common among individuals with BGC in unadjusted analyses, but this association was not significant after adjustment for age and sex. Conclusion: BGCs were not associated with stroke or SVD‐related stroke in this cohort. However, we identified a statistically significant association between SAH and mild‐to‐moderate BGC. This may indicate a link to specific vascular pathologies. Overall, BGC may represent an age‐related finding rather than a marker of clinically relevant SVD.

  • Blood Biospecimen Recommendations for Research on Stroke Outcomes and Recovery

    by Robynne G. Braun, Matthew A. Edwardson, Chad M. Aldridge, Steven C. Cramer, Carlos Cruchaga, Stefan T. Engelter, Jin-Moo Lee, Jane M. Maguire, Tara M. Stanne, Boryana Stamova, et al.

    The impact of trait-associated genetic variants on stroke risk is by now a well-established area of research that has continued to accelerate since the introduction of genome-wide technologies. More recently, the field has seen an increasing interest in the biology of stroke recovery. Studies designed to evaluate stroke recovery have unique needs that differ from those in studies of stroke risk and acute stroke outcomes. Here we outline the essential considerations for researchers aiming to develop or contribute to blood biomarker research on stroke recovery. Our recommendations incorporate the latest evidence and technologies that have emerged since the prior International Stroke Genetics Consortium Global Alliance recommendations were published in 2015. Nominated contributors with expertise in stroke recovery and genomics met over the course of 9 months and defined the scope of topics, discussed current practice and standards, and revised the recommendations to reflect consensus achieved through 2 rounds of anonymized surveys. Our writing group defined an updated and expanded set of recommendations applicable to a range of research priorities including (1) elucidating the biology of stroke recovery, (2) determining genetic variations associated with good versus poor stroke outcomes and recovery, (3) identifying druggable (or otherwise therapeutically actionable) gene or protein targets for enhanced recovery, and (4) identifying blood biomarkers that can predict stroke outcomes and recovery. The resulting work offers comprehensive guidance on essential preanalytical considerations for blood biomarker studies, encompassing blood collection timing, specimen processing and storage procedures, and regulatory aspects such as informed consent and data sharing. These guidelines will enable the consistent collection of human data on recovery biology at scale, providing the foundational evidence necessary to drive subsequent clinical translation.


  • Open Access

    Brain Health Loss Mediates the Effect of Infarct Volume on Functional Outcome in Ischemic Stroke

    by Erik Lindgren, Luca Angeleri, Kenda Alhadid, Christina Jern, Arne G. Lindgren, Jane Maguire, Robert W. Regenhardt, Natalia S. Rost, Markus D. Schirmer

    Structured Importance: Brain health may facilitate resilience to detrimental consequences from neurological diseases. Infarct volume is associated with poor functional outcome after acute ischemic stroke (AIS), but potential mediating effects through stroke-related brain health loss have not been investigated. Objective: To determine whether stroke-related brain health loss, quantified by change in MRI derived effective Reserve (eR), mediates the effect of acute infarct volume on functional outcome after AIS. Design: Observational multicenter cohort study. Setting: We analyzed data from the GASROS (n=488) and MRI-GENIE (n=560) cohorts, collected 2003-2011. Participants: Adult patients consecutively diagnosed with AIS, with available admission MRI. Exposure: At admission, white matter hyperintensity (WMH) and normal-appearing brain volumes were assessed on T2-FLAIR, and acute infarct volume on diffusion weighted imaging. WMH was normalized by brain volume, creating WMH load. We quantified brain health using eR, a latent variable incorporating age, WMH load, and normal-appearing brain volume. ΔeR reflected the change in eR when acute infarct volume was included, representing stroke-related brain health decline. Mediation analysis was used to determine if ΔeR mediates the effect of infarct volume on functional outcome (modified Rankin Scale [mRS] at 90 days). Main Outcome Measure: Proportion of mediating effect. Results: We included 1,048 patients (median age 67y, 38% females). At baseline, median NIHSS score was 3 (IQR 1-7), median infarct volume 3.1mL (IQR 0.9-15.5). At 90 days, median mRS score was 1 (IQR 1-3) and 51 (5%) patients had died. In mediation analysis, ΔeR significantly mediated 36% (95% CI 16-56%) of the total effect of infarct volume on functional outcome (direct effect (ß=0.15 [95% CI 0.09-0.22], p67y but not ≤67y. Conclusions and Relevance: Stroke-related structural brain health loss mediates about one third of the effect of acute infarct volume on functional outcome after ischemic stroke, with important sex and age differences. Brain health significantly influences outcome and recovery potential, and may be considered a key biomarker when modeling outcome after AIS. Key points: Question: Does brain health loss associated with acute ischemic stroke mediate the relationship between acute infarct volume and functional outcome? Findings: In this observational multicenter cohort study of 1,048 patients, mediation analysis suggests that reduction of the brain health MRI marker effective Reserve mediates 36% (95% CI 16-56%) of the total effect of acute infarct volume on functional outcome. The proportion of mediative effect was more pronounced among female compared to male and in older compared to younger patients. Meaning: Brain health loss mediates one third of the effect of acute infarct volume on functional outcome after ischemic stroke.

  • Open Access

    Time to consider health services dedicated for adults living with cerebral small vessel disease: Report of a ESO scientific seminar

    by Carmen Arteaga-Reyes, Dwaipayan Sen, Salvatore Rudilosso, Eric Jouvent, Dominique Hervé, Arne G Lindgren, Joanna M Wardlaw, Susanna Melkas, Fergus N Doubal

    Purpose: Cerebral small vessel disease (cSVD) is a highly prevalent disorder leading to physical, cognitive and functional decline. We report key barriers in the management of individuals with cSVD, the potential benefit of cSVD-dedicated health services, and evidence from existing models of care for adults with cSVD. Methods: We examined information from a scientific seminar developed between seven experts in cSVD during the eighth European Stroke Organisation Conference that discussed the optimal health care for adults with cSVD and what health services dedicated to cSVD should include. Findings: Barriers in cSVD care include unrecognised symptoms and modifiable risk factors, heterogeneity of clinical presentations, inefficient inter/intra-clinical services communication/organisation, and uncertainties regarding what assessments/treatments should be routinely done, when and by whom. However, existing health services and research studies suggest models of care in cSVD. Multi-step approaches can be used for identification and aetiological workup in individuals with cSVD, including basic and selected advanced evaluations, for example, monogenic cSVD testing. Although current guidelines for management of cSVD illlustrate limitations, there are recommendations on risk factors and lifestyle considerations, as well as pharmacological and non-pharmacological interventions for people with cSVD. Discussion and conclusion: Existing healthcare models do not provide optimal care for individuals with cSVD. Lack of awareness of heterogeneous clinical presentations and uncertainty in threshold of cSVD ‘burden’ for referral to specialist multidisciplinary services, are key challenges for health services to overcome. Creating cSVD-dedicated services may prevent underdiagnosing and achieve standardised holistic management to improve outcomes in people with cSVD. However, adequate prevention and early management should be offered at all levels of care.


  • Open Access

    Orthopaedic manual physical therapy for post-stroke shoulder pain: two case reports including clinical assessments and participants’ experiences

    by Ingrid Lindgren, Arne G. Lindgren, Håkan Carlsson, Tobias Lundgren, Christina Brogårdh

    Objective: To descriptively evaluate Orthopaedic Manual Physical Therapy – a novel intervention for post-stroke shoulder pain – by use of clinical assessments and the participants’ experiences. Design: Two case reports. Methods: Two individuals with mild to moderate upper extremity impairments and persistent post-stroke shoulder pain, underwent Orthopaedic Manual Physical Therapy for 12 weeks. The intervention comprised a thorough clinical examination, joint mobilization, stretching, and exercises targeting the affected structures and incorrect movement patterns. Participants were clinically assessed pre- and post-intervention and followed up 4–5 months later. They also answered interviews about their experiences of the intervention and perceived effects. Results: After Orthopaedic Manual Physical Therapy, both participants showed decreased pain intensity during movements and increased range of motion. One of the participants also experienced decreased resistance to passive movements, improved motor function, grip strength, and upper extremity daily activities after the intervention and at follow-up. Interviews revealed that the participants tolerated the therapy well and were satisfied with the intervention and long-lasting results. Conclusion: Orthopaedic Manual Physical Therapy may be a useful method to reduce post-stroke shoulder pain in persons with mild to moderate upper extremity paresis after stroke. To confirm the results, further studies are warranted.